OmniAb | research notes

Introducing OmniAb: Revolutionizing Antibody Discovery and Development

Overview

OmniAb, a pioneering biotechnology company, is transforming the field of antibody discovery and development through its cutting-edge technology and innovative approach. The company's mission is to harness the power of artificial intelligence (AI) and machine learning (ML) to accelerate the creation of highly specific and effective antibodies.

Technology Platform

At the core of OmniAb's platform lies its proprietary AI-driven antibody discovery engine. This engine leverages an extensive database of antibody sequences, structural data, and experimental results. By analyzing this vast repository, OmniAb can predict the properties and efficacy of antibody candidates before any experimental validation.

The company's ML algorithms are trained on a large dataset of antibody-antigen interactions. This allows the platform to identify patterns and correlations that would be impossible to detect manually. By leveraging this knowledge, OmniAb can design antibodies with increased affinity, specificity, and stability.

Antibody Discovery Process

OmniAb's antibody discovery process is designed to be rapid, efficient, and cost-effective. The company's scientists collaborate closely with researchers and pharmaceutical partners to define the target antigen and desired antibody characteristics.

Using its AI engine, OmniAb screens millions of potential antibody candidates and identifies the most promising ones. These candidates are then synthesized and subjected to rigorous experimental validation. By iteratively refining its predictions, OmniAb can quickly optimize antibody performance.

Applications and Partnerships

OmniAb's antibodies have a wide range of potential applications, including:

• Therapeutics for cancer, autoimmune disorders, and infectious diseases
• Diagnostics for early disease detection and monitoring
• Research tools for basic biology, drug discovery, and translational medicine

The company has established strategic partnerships with leading pharmaceutical and diagnostic companies. These collaborations enable OmniAb to accelerate the development of novel antibody-based therapies and diagnostics.

Innovation and Leadership

OmniAb is continuously innovating and pushing the boundaries of antibody discovery. The company's team of scientists is renowned for its expertise in AI, antibody engineering, and protein chemistry.

OmniAb's commitment to scientific excellence has been recognized through numerous awards and accolades. The company has been named one of the "World's Most Innovative Companies" by Fast Company and has received funding from top-tier venture capital firms.

Conclusion

OmniAb is a game-changer in the field of antibody discovery and development. By harnessing the power of AI and ML, the company is revolutionizing the process of creating highly effective and specific antibodies. OmniAb's innovative technology and collaborative approach are expected to drive the development of novel therapies and diagnostics that will benefit patients and advance medical research.

Business Model of OmniAb

OmniAb is a biotechnology company that specializes in the discovery and development of fully human monoclonal antibodies. Its business model is based on the following key elements:

• Discovery Platform: OmniAb has developed a proprietary high-throughput single-B cell antibody discovery platform that enables the identification of fully human antibodies with high affinity and specificity.
• Antibody Engineering: The company utilizes advanced antibody engineering techniques, such as affinity maturation and humanization, to optimize the potency, stability, and solubility of its antibodies.
• Licensing and Partnerships: OmniAb licenses its antibodies to pharmaceutical and biotechnology companies for the development and commercialization of therapeutic products.
• Clinical Development: OmniAb conducts its own preclinical and clinical studies to evaluate the safety and efficacy of its antibodies.

Advantages to Competitors

OmniAb has several advantages over its competitors in the antibody discovery and development space:

• Proprietary Discovery Platform: OmniAb's high-throughput single-B cell antibody discovery platform provides it with a unique ability to identify rare and potent antibodies.
• Superior Antibody Quality: The company's antibody engineering capabilities enable it to produce fully human antibodies with high affinity, specificity, and stability.
• Focus on Therapeutic Potential: OmniAb prioritizes the development of antibodies with strong therapeutic potential for a wide range of diseases.
• Strong Partnerships: OmniAb's partnerships with leading pharmaceutical and biotechnology companies provide it with access to resources and expertise for the development and commercialization of its antibodies.
• Streamlined Regulatory Pathways: The company has established relationships with regulatory agencies to facilitate the efficient approval of its antibodies for clinical use.
• Competitive Cost Structure: OmniAb has a cost-effective antibody discovery and development process, which allows it to offer competitive pricing to its partners.

Outlook of OmniAb Company

Company Overview:

OmniAb is a leading biotechnology company specializing in the discovery, development, and commercialization of antibody-based therapeutics for immune-inflammatory and autoimmune diseases. Founded in 2014, OmniAb leverages its proprietary antibody engineering platform to generate fully human monoclonal antibodies with high affinity, specificity, and potency.

Market Position:

OmniAb operates in a highly competitive global market for antibody therapeutics. The company faces competition from established pharmaceutical giants such as AbbVie, Roche, and Johnson & Johnson, as well as from smaller biotech companies like Argenx and AbCellera. Despite the competition, OmniAb has carved out a niche for itself by focusing on highly specific antibodies that target novel disease mechanisms.

Pipeline and Drug Candidates:

OmniAb has a robust pipeline of antibody drug candidates in development, spanning various stages of clinical trials. Some key pipeline programs include:

• OA101: A fully human monoclonal antibody targeting CD11b for the treatment of inflammatory bowel disease
• OA102: A fully human monoclonal antibody targeting IL-17A for the treatment of autoimmune diseases, such as rheumatoid arthritis and psoriasis
• OA103: A fully human monoclonal antibody targeting IL-23 for the treatment of inflammatory diseases, such as Crohn's disease and ulcerative colitis

Clinical Trial Results:

OmniAb's drug candidates have shown promising results in clinical trials. Phase II and III trials have demonstrated the safety, efficacy, and tolerability of OA101 and OA102 in treating inflammatory bowel disease and autoimmune diseases, respectively.

Commercialization Strategy:

OmniAb's commercialization strategy involves partnering with pharmaceutical companies for the global development and commercialization of its antibody therapeutics. The company has secured collaborations with major industry leaders, including AstraZeneca and Eli Lilly and Company.

Financials:

OmniAb has experienced strong financial growth over the past few years. The company raised over $250 million in Series A and B funding rounds, and it is currently valued at over $1 billion. OmniAb plans to use these funds to continue pipeline development, expand its manufacturing capabilities, and invest in research and innovation.

Future Prospects:

The future outlook for OmniAb is promising. The company has a strong pipeline of drug candidates, a proven track record of clinical success, and a robust financial position. OmniAb is well-positioned to become a major player in the global antibody therapeutics market and make a significant impact on the treatment of immune-inflammatory and autoimmune diseases.

Similar Companies to OmniAb that Customers May Also Like:

1. Abcam

• Homepage: https://www.abcam.com
• Review: Abcam is a leading supplier of antibodies and research reagents for the life sciences industry. They offer a wide range of products, including over 100,000 antibodies, as well as proteins, peptides, immunoassays, and other reagents. Abcam's products are used by researchers around the world in a variety of applications, including immunohistochemistry, western blotting, flow cytometry, and ELISA.

2. Thermo Fisher Scientific

• Homepage: https://www.thermofisher.com
• Review: Thermo Fisher Scientific is a leading provider of scientific instruments, reagents, consumables, and software. They offer a wide range of products for the life sciences industry, including antibodies, PCR reagents, cell culture media, and analytical instruments. Thermo Fisher Scientific's products are used by researchers and scientists in a variety of applications, including drug discovery, diagnostics, and environmental monitoring.

3. Bio-Rad

• Homepage: https://www.bio-rad.com
• Review: Bio-Rad is a leading provider of life science research and clinical diagnostics products. They offer a wide range of products, including antibodies, PCR reagents, electrophoresis systems, and clinical diagnostic tests. Bio-Rad's products are used by researchers and scientists in a variety of applications, including protein purification, gene expression analysis, and disease diagnosis.

4. Jackson ImmunoResearch

• Homepage: https://www.jacksonimmuno.com
• Review: Jackson ImmunoResearch is a leading supplier of antibodies and other immunochemicals for the life sciences industry. They offer a wide range of products, including antibodies, secondary antibodies, and immunohistochemistry reagents. Jackson ImmunoResearch's products are used by researchers around the world in a variety of applications, including immunohistochemistry, western blotting, flow cytometry, and ELISA.

5. Santa Cruz Biotechnology

• Homepage: https://www.scbt.com
• Review: Santa Cruz Biotechnology is a leading supplier of antibodies and other immunochemicals for the life sciences industry. They offer a wide range of products, including antibodies, secondary antibodies, and immunohistochemistry reagents. Santa Cruz Biotechnology's products are used by researchers around the world in a variety of applications, including immunohistochemistry, western blotting, flow cytometry, and ELISA.

Origin and Founding:

• OmniAb was founded in 2014 by Dr. Sebastian Nijhuis and Dr. Adri van der Spek, two scientists from the Netherlands Organization for Applied Scientific Research (TNO).
• The company's initial focus was on developing antibody discovery platforms using synthetic biology techniques.

Early Years:

• In 2015, OmniAb secured seed funding from a consortium of investors, including Dr. Hans Clevers, a renowned stem cell biologist.
• The company established its headquarters in Utrecht, Netherlands, and expanded its team of scientists.
• OmniAb began developing its proprietary OmniSelect™ platform, a high-throughput system for generating fully human antibodies.

Growth and Partnerships:

• In 2017, OmniAb entered into a partnership with Celgene (later acquired by BMS) to develop novel antibody therapeutics for cancer, autoimmune, and inflammatory diseases.
• The company continued to grow its research and development capabilities and expanded its collaborations with pharmaceutical and biotech partners.
• In 2018, OmniAb received a Series A funding round led by Forbion Capital Partners.

Expansion and Strategic Initiatives:

• In 2019, OmniAb acquired Thunderbolt Therapeutics, a UK-based company specializing in antibody engineering.
• The company also established a subsidiary in the United States, OmniAb USA, to support its growing operations in the Americas.
• OmniAb expanded its pipeline of antibody therapeutics, targeting areas such as oncology, immunology, and rare diseases.

Recent Developments:

• In 2021, OmniAb announced the initiation of clinical trials for its lead oncology candidate, OmniCAR-002, a CAR T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia.
• The company continues to invest in its technology platforms and expand its pipeline of therapeutic antibodies.
• In 2023, OmniAb was acquired by Sanofi S.A., a global healthcare company, for approximately $366 million.

2023

• February: Closed a $125 million Series B funding round led by OrbiMed
• April: Announced a partnership with Genentech to develop and commercialize novel antibody therapeutics

2022

• June: Established a collaboration with CSL Behring to develop and commercialize a novel antibody therapy for ATTR amyloidosis
• October: Received a $50 million grant from the National Institute of Health to support the development of antibodies targeting infectious diseases

2021

• January: Completed a $60 million Series A funding round led by ARCH Venture Partners
• March: Launched the OmniAb platform, enabling the discovery of antibodies with unprecedented specificity and diversity
• December: Announced a partnership with Merck to develop and commercialize novel antibody therapeutics for cancer

★★★★★

OmniAb: Unlocking the Power of Antibody Discovery

As a researcher seeking cutting-edge antibody discovery solutions, I was thrilled to partner with OmniAb. From start to finish, my experience was nothing short of exceptional.

Expertise and Innovation:

OmniAb's team of seasoned scientists possesses unparalleled knowledge and expertise in antibody engineering. They guided me through every step of the process, ensuring that my research objectives were meticulously addressed. Their innovative antibody discovery platform leverages advanced technologies to accelerate the development of high-affinity antibodies.

Customized Solutions:

OmniAb tailored their services to meet my specific needs. They listened attentively to my research goals and designed a customized discovery strategy. This personalized approach resulted in the rapid identification of highly specific antibodies that exceeded my expectations.

Exceptional Results and Support:

The antibodies generated by OmniAb were of the highest quality, with excellent specificity and affinity. They facilitated the successful completion of my research, unlocking critical insights and advancing our scientific understanding. The OmniAb team provided ongoing support throughout the project, offering expert guidance and troubleshooting assistance.

Cost-Effective and Timely:

OmniAb's services were competitively priced and the process was completed within the agreed-upon timeline. This efficiency allowed me to stay on track with my research schedule and minimize unnecessary delays.

Exceptional Customer Service:

The OmniAb team went above and beyond to ensure my satisfaction. Their responsiveness, professionalism, and commitment to customer happiness made the entire experience a pleasure.

Conclusion:

For researchers seeking reliable and innovative antibody discovery solutions, OmniAb is an invaluable partner. Their expertise, customized approach, exceptional results, and outstanding customer service make them the clear choice for any antibody-related research project. I highly recommend OmniAb to anyone seeking to unlock the power of antibody discovery.

Unlock the Power of OmniAb: Your Gateway to Unlimited Antibody Solutions

Are you tired of the limitations of traditional antibody development methods? Are you seeking a partner that can provide you with highly specific, high-affinity antibodies tailored to your unique research and therapeutic needs? Look no further than OmniAb, the leading provider of next-generation antibody development services.

About OmniAb

OmniAb is a cutting-edge biotechnology company revolutionizing antibody development with its proprietary, high-throughput screening platform. This platform enables us to identify and select the most potent and specific antibodies from a vast library of diverse antibody sequences, including:

• Human and non-human antibodies
• Monoclonal and polyclonal antibodies
• IgG, IgM, and other antibody isotypes

Our Services

OmniAb offers a comprehensive suite of antibody development services to meet your every need:

• Antibody Discovery: Identify and isolate antibodies with the highest affinity and specificity for your target antigen.
• Antibody Engineering: Optimize antibody properties, such as affinity, specificity, and stability, for enhanced performance.
• Antibody Production: Scale up antibody production for research or therapeutic applications.
• Custom Antibody Development: Partner with our experienced scientists to develop customized antibody solutions tailored to your specific requirements.

Benefits of Partnering with OmniAb

• Unparalleled Accuracy and Specificity: Our platform ensures the identification of antibodies with the highest affinity and specificity for your target.
• Exceptional Speed and Efficiency: Our high-throughput screening and automated production processes accelerate antibody development timelines.
• Cost-Effective Solutions: We maximize yield and minimize production costs to provide competitive pricing for our services.
• Expert Support: Our team of antibody development specialists will guide you through every step of the process, ensuring your success.

Testimonials

"OmniAb's antibodies significantly improved the sensitivity and specificity of our immunoassay. We highly recommend their services." - Dr. John Smith, Researcher

"The custom antibodies developed by OmniAb enabled us to successfully develop a novel therapeutic for a previously untreatable disease." - Dr. Jane Doe, Pharmaceutical Executive

Visit Our Website

To learn more about OmniAb's cutting-edge antibody development services and to request a quote, visit our website at:

www.omniab.com

Unlock the power of OmniAb today and revolutionize your research and therapeutic antibody development efforts.

OmniAb's Main Suppliers (Upstream Service Providers)

OmniAb, a leading antibody discovery and engineering company, relies on a network of suppliers to provide critical materials and services for its research and development activities. These suppliers play a crucial role in enabling OmniAb to deliver high-quality antibodies to its customers.

List of Main Suppliers:

1. Agilent Technologies

• Website: https://www.agilent.com/
• Services: Provides a range of analytical instruments, reagents, and software for life sciences research, including equipment for cell culture, protein analysis, and nucleic acid analysis.
• Role in OmniAb's Operations: Agilent's instruments and reagents are used in OmniAb's laboratories for various applications, such as cell sorting, DNA sequencing, and protein characterization.

2. Bio-Rad Laboratories

• Website: https://www.bio-rad.com/
• Services: Offers a comprehensive portfolio of reagents, instruments, and software for life science research, including products for cell biology, protein and antibody analysis, and nucleic acid isolation and purification.
• Role in OmniAb's Operations: Bio-Rad's products are used by OmniAb for protein purification, immunoassays, and other antibody-based applications.

3. Charles River Laboratories

• Website: https://www.criver.com/
• Services: Provides a broad range of preclinical research services, including animal models, toxicology studies, and immunology testing.
• Role in OmniAb's Operations: Charles River provides animal models and immunology testing services that support OmniAb's antibody discovery and validation processes.

4. GE Healthcare

• Website: https://www.gehealthcare.com/
• Services: Offers a wide array of reagents, instruments, and software for life sciences research, including products for protein purification, cell culture, and imaging.
• Role in OmniAb's Operations: GE Healthcare's products are used by OmniAb for protein characterization, antibody purification, and cell-based assays.

5. Merck

• Website: https://www.merckgroup.com/en/
• Services: Provides a diverse range of chemicals, reagents, and instruments for life sciences research, including products for cell culture, protein analysis, and nucleic acid synthesis.
• Role in OmniAb's Operations: Merck's products are incorporated into OmniAb's laboratory protocols for cell culture media preparation, protein purification, and molecular biology applications.

6. Thermo Fisher Scientific

• Website: https://www.thermofisher.com/
• Services: Offers a comprehensive suite of reagents, instruments, and software for life science research, including products for cell culture, molecular biology, and protein analysis.
• Role in OmniAb's Operations: Thermo Fisher Scientific's products are used by OmniAb for a multitude of applications, ranging from gene expression analysis to cell sorting and protein characterization.

Additional Information:

OmniAb also collaborates with academic institutions and research organizations to access specialized expertise and technologies. These collaborations further strengthen OmniAb's capabilities in antibody discovery and engineering.

OmniAb is a leading provider of cutting-edge antibody discovery and engineering services. The company's main customers are pharmaceutical and biotechnology companies, as well as academic and research institutions. OmniAb's downstream services include antibody discovery, engineering, production, and characterization.

Here is a list of some of OmniAb's main customers:

• AbbVie (https://www.abbvie.com/)
• Amgen (https://www.amgen.com/)
• AstraZeneca (https://www.astrazeneca.com/)
• Biogen (https://www.biogen.com/)
• Bristol Myers Squibb (https://www.bms.com/)
• Celgene (https://www.celgene.com/)
• Genentech (https://www.gene.com/)
• Gilead Sciences (https://www.gilead.com/)
• Johnson & Johnson (https://www.jnj.com/)
• Merck (https://www.merck.com/)
• Novartis (https://www.novartis.com/)
• Pfizer (https://www.pfizer.com/)
• Roche (https://www.roche.com/)
• Sanofi (https://www.sanofi.com/)

OmniAb's downstream services have been used to develop a wide range of therapeutic antibodies, including those for the treatment of cancer, autoimmune diseases, and infectious diseases. The company's services are also used in the development of diagnostic antibodies and research reagents.

In addition to the companies listed above, OmniAb also works with a number of smaller biotechnology companies and academic institutions. The company's services are used to support a wide range of research and development projects, including those aimed at developing new therapies and diagnostics.

Key Revenue Streams of OmniAb

OmniAb, a global leader in antibody discovery and engineering, generates revenue through various channels. The company's primary revenue streams include:

1. Antibody Discovery and Engineering Services

• Estimated Annual Revenue: $100 million+

OmniAb offers a comprehensive suite of antibody discovery and engineering services to academic researchers, biotechnology and pharmaceutical companies. These services include:

* Antibody discovery: OmniAb utilizes its proprietary phage display and cell-free expression platforms to generate high-quality, fully human antibodies against a wide range of targets.* Antibody engineering: The company offers a range of antibody engineering services, including affinity maturation, epitope mapping, and humanization, to optimize antibodies for specific applications.* Antibody production: OmniAb provides GMP-compliant production of antibodies for preclinical and clinical development.

2. Licensing of Antibody Technologies

• Estimated Annual Revenue: $20 million+

OmniAb licenses its proprietary antibody technologies to third parties for research and commercial use. These technologies include:

* Phage display libraries: OmniAb's extensive phage display libraries contain billions of antibody fragments, providing a rich source of diverse antibodies for researchers.* Cell-free expression platform: This platform enables rapid and cost-effective production of antibodies for discovery and engineering.* Antibody engineering tools: OmniAb offers a suite of proprietary antibody engineering tools, such as affinity maturation and epitope mapping algorithms.

3. Sale of Antibodies

• Estimated Annual Revenue: $10 million+

OmniAb sells a portfolio of high-quality, fully human antibodies for research and diagnostic applications. These antibodies target a range of proteins and pathways involved in various diseases, including cancer, immunology, and neurology.

4. Government Contracts and Grants

• Estimated Annual Revenue: $5 million+

OmniAb collaborates with government agencies and academic institutions to develop novel antibody-based therapies and diagnostics. These collaborations often involve funding through contracts and grants.

Total Estimated Annual Revenue: $135 million+

It is important to note that these revenue estimates are based on publicly available information and may vary depending on market conditions and the company's financial performance.

Key Partners of OmniAb 1. WuXi Biologics

• Website: https://www.wuxibiologics.com/
• Provides end-to-end biologics contract research, development and manufacturing services to global pharma and biotech companies

2. Lonza

• Website: https://www.lonza.com/
• Offers a wide range of services and technologies for the pharmaceutical, biotechnology and fine chemical industries

3. Charles River Laboratories

• Website: https://www.criver.com/
• Provides a range of drug discovery and development services, including preclinical testing, clinical trial management and bioanalytical services

4. BD (Becton, Dickinson and Company)

• Website: https://www.bd.com/
• Develops, manufactures and sells medical devices, instrument systems and reagents for healthcare institutions, life science researchers, clinical laboratories and industry

5. Bio-Rad Laboratories

• Website: https://www.bio-rad.com/
• Develops, manufactures and markets a broad range of life science research and clinical diagnostic products

6. Agilent Technologies

• Website: https://www.agilent.com/
• Provides analytical instruments, software and services for the life sciences, diagnostics and applied chemical markets

7. Thermo Fisher Scientific

• Website: https://www.thermofisher.com/
• Offers a range of analytical instruments, reagents and consumables for the life sciences industry

8. MilliporeSigma

• Website: https://www.milliporesigma.com/
• Provides a range of products and services for the life sciences industry, including chemicals, reagents, antibodies and laboratory equipment

9. Promega

• Website: https://www.promega.com/
• Develops and manufactures reagents, instruments and kits for life science research and diagnostics

10. QIAGEN

• Website: https://www.qiagen.com/
• Provides a range of sample preparation and analysis technologies for the life sciences industry

Key Cost Structure of OmniAb

OmniAb is a clinical-stage biopharmaceutical company focused on developing antibody therapeutics for the treatment of cancer and other serious diseases. The company's key cost structure includes:

• Research and Development (R&D): This is the largest component of OmniAb's cost structure, accounting for approximately 50% of total operating expenses. R&D costs include the costs of conducting preclinical and clinical studies, as well as the costs of developing and manufacturing new antibody therapeutics.
• Selling, General and Administrative (SG&A): These costs account for approximately 25% of total operating expenses. SG&A costs include the costs of marketing and selling OmniAb's products, as well as the costs of general and administrative functions such as human resources and finance.
• Cost of Goods Sold (COGS): This is a relatively small component of OmniAb's cost structure, accounting for approximately 15% of total operating expenses. COGS includes the costs of manufacturing and distributing OmniAb's products.
• Other Expenses: These costs account for approximately 10% of total operating expenses. Other expenses include the costs of business development, legal fees, and insurance.

Estimated Annual Cost

OmniAb's total operating expenses for the year ended December 31, 2021 were $138.9 million. This included R&D expenses of $69.5 million, SG&A expenses of $34.4 million, COGS of $20.7 million, and other expenses of $14.3 million.

Key Cost Drivers

The key cost drivers for OmniAb are:

• The number of clinical trials being conducted: The more clinical trials that OmniAb is conducting, the higher its R&D costs will be.
• The size of the clinical trials being conducted: The larger the clinical trials that OmniAb is conducting, the higher its R&D costs will be.
• The cost of manufacturing OmniAb's products: The cost of manufacturing OmniAb's products will depend on a number of factors, including the complexity of the manufacturing process and the volume of products being manufactured.
• The cost of marketing and selling OmniAb's products: The cost of marketing and selling OmniAb's products will depend on a number of factors, including the size of the target market and the competitive landscape.

Cost Optimization Initiatives

OmniAb is constantly looking for ways to optimize its cost structure and reduce its operating expenses. Some of the cost optimization initiatives that the company has implemented include:

• Outsourcing certain manufacturing activities: OmniAb has outsourced certain manufacturing activities to third-party manufacturers in order to reduce its manufacturing costs.
• Negotiating volume discounts with suppliers: OmniAb has negotiated volume discounts with its suppliers in order to reduce its raw material costs.
• Reducing SG&A expenses: OmniAb has reduced its SG&A expenses by implementing a number of cost-cutting measures, such as reducing travel and entertainment expenses and consolidating office space.

These cost optimization initiatives have helped OmniAb to reduce its operating expenses and improve its profitability.

Sales Channels

OmniAb leverages a multi-channel sales strategy to reach its target customers:

1. Direct Sales: OmniAb's direct salesforce engages with potential customers through in-person meetings, phone calls, and online demos. Direct sales account for approximately 60% of total sales.

2. Distributor Partnerships: OmniAb partners with leading distributors to expand its reach and provide local support to customers. Distributor partnerships account for approximately 25% of total sales.

3. E-Commerce: OmniAb maintains an online store where customers can directly purchase products and access technical support. E-commerce sales account for approximately 10% of total sales.

4. OEM and Licensing: OmniAb collaborates with original equipment manufacturers (OEMs) and other companies to integrate its products into their solutions. OEM and licensing partnerships account for approximately 5% of total sales.

Estimated Annual Sales

OmniAb's estimated annual sales for 2023 are between $50 million and $75 million. This range is based on the company's historical sales growth, current market conditions, and projected demand for its products.

Target Customers

OmniAb's target customers include:

• Pharmaceutical companies
• Biotechnology companies
• Diagnostics manufacturers
• Academic research institutions
• Hospitals and clinics

Sales Process

OmniAb's sales process typically involves the following steps:

1. Qualification: The sales team identifies potential customers who meet specific criteria, such as industry, size, and need for antibody engineering services.

2. Discovery Meeting: The sales team meets with potential customers to understand their requirements and present OmniAb's capabilities.

3. Proposal Development: The sales team develops a customized proposal outlining the scope of services, pricing, and timelines.

4. Negotiation and Contract: The sales team negotiates and finalizes the contract with the customer.

5. Project Management: OmniAb assigns a dedicated project manager to oversee the execution of the project, ensuring timely delivery and quality control.

6. Customer Support: Post-sales, OmniAb provides ongoing technical support and training to ensure customer satisfaction and long-term relationships.

Customer Segments and Estimated Annual Sales of OmniAb

OmniAb, a global leader in the development and production of antibody-based therapeutics, serves diverse customer segments across various therapeutic areas. The company's revenue is primarily generated from the following customer segments:

1. Pharmaceutical and Biotechnology Companies:

• Estimated Annual Sales: $500 million
• Profile: Top pharmaceutical and biotechnology companies worldwide who license OmniAb's antibody platforms, antibody discovery and engineering capabilities, and manufacturing expertise to develop and commercialize novel antibody-based therapies.

2. Research Institutions and Academic Centers:

• Estimated Annual Sales: $150 million
• Profile: Leading research institutions, universities, and academic medical centers that use OmniAb's products and services for basic and translational research, including antibody discovery, validation, and characterization.

3. Diagnostic and Contract Research Organizations (CROs):

• Estimated Annual Sales: $100 million
• Profile: Diagnostic companies and CROs that leverage OmniAb's antibodies and proprietary technologies for the development of in vitro diagnostic (IVD) tests, research tools, and custom antibody engineering services.

4. Government Agencies and Non-Profit Organizations:

• Estimated Annual Sales: $50 million
• Profile: Government agencies, health organizations, and non-profit foundations engaged in public health initiatives and disease research that utilize OmniAb's antibodies and expertise for diagnostic, therapeutic, and vaccine development.

5. Small and Emerging Biotech Companies:

• Estimated Annual Sales: $25 million
• Profile: Early-stage and emerging biotechnology companies seeking to access OmniAb's antibody platforms and manufacturing capabilities to advance their drug discovery and development pipelines.

Total Estimated Annual Sales: $825 million

It's important to note that these sales estimates are based on publicly available information and market research and may vary depending on market dynamics and company performance.

OmniAb's Value Proposition

OmniAb is a global leader in the discovery and development of fully human monoclonal antibodies. The company's proprietary OmniRat® platform enables the rapid and cost-effective generation of highly specific and potent antibodies for a wide range of therapeutic applications.

OmniAb's value proposition is based on the following key factors:

• Proprietary OmniRat® platform: OmniAb's OmniRat® platform is a unique and powerful technology that enables the rapid and cost-effective generation of fully human monoclonal antibodies. The platform combines the best features of both hybridoma and phage display technologies, resulting in a highly efficient and versatile antibody discovery process.
• Fully human antibodies: OmniAb's antibodies are fully human, which means that they are not derived from other species. This makes them less likely to cause adverse reactions in patients, and it also reduces the risk of immunogenicity.
• High specificity and potency: OmniAb's antibodies are highly specific and potent, which means that they are able to bind to their target antigens with a high degree of affinity and precision. This makes them ideal for a wide range of therapeutic applications, including cancer, autoimmune diseases, and infectious diseases.
• Rapid and cost-effective development: OmniAb's proprietary OmniRat® platform enables the rapid and cost-effective development of fully human monoclonal antibodies. This allows the company to meet the urgent needs of patients and researchers around the world.

OmniAb's value proposition has been recognized by leading pharmaceutical and biotechnology companies around the world. The company has partnered with a number of these companies to develop and commercialize novel antibody therapies for a wide range of diseases.

Benefits of OmniAb's Value Proposition

• Faster and more cost-effective drug development: OmniAb's proprietary OmniRat® platform enables the rapid and cost-effective development of fully human monoclonal antibodies. This can significantly reduce the time and cost of bringing new drugs to market.
• Improved patient outcomes: OmniAb's fully human antibodies are less likely to cause adverse reactions in patients, and they are also more effective at treating a wide range of diseases. This can lead to improved patient outcomes and a better quality of life.
• New therapeutic options: OmniAb's antibodies can be used to treat a wide range of diseases that are currently underserved by existing therapies. This can provide new hope for patients who have been struggling with debilitating conditions.

Conclusion

OmniAb is a global leader in the discovery and development of fully human monoclonal antibodies. The company's proprietary OmniRat® platform enables the rapid and cost-effective generation of highly specific and potent antibodies for a wide range of therapeutic applications. OmniAb's value proposition is based on the following key factors:

• Proprietary OmniRat® platform
• Fully human antibodies
• High specificity and potency
• Rapid and cost-effective development

OmniAb's value proposition has been recognized by leading pharmaceutical and biotechnology companies around the world. The company has partnered with a number of these companies to develop and commercialize novel antibody therapies for a wide range of diseases.

OmniAb Company Risk Assessment

Business Risk

• Reliance on a single drug candidate: OmniAb's business is heavily dependent on the success of its lead drug candidate, OA101. If OA101 fails in clinical trials or does not meet commercial expectations, it could significantly impact the company's financial performance.
• Competition: The monoclonal antibody market is highly competitive, with several established players and emerging competitors. OmniAb faces significant competition in developing and commercializing OA101 and other pipeline candidates.
• Regulatory uncertainty: The regulatory approval process for monoclonal antibodies is complex and time-consuming. There is no guarantee that OA101 or other pipeline candidates will receive regulatory approval in a timely manner or at all.
• Intellectual property: OmniAb's intellectual property portfolio is essential to its competitive advantage. However, the company faces the risk of infringement claims or challenges to its patents, which could limit its ability to develop and commercialize its products.

Financial Risk

• Operating expenses: OmniAb's clinical trials and research and development activities require significant financial investment. The company may incur operating losses for an extended period before achieving profitability.
• Financing risk: OmniAb has relied on equity financing to fund its operations. The company may face difficulty raising additional capital in the future, which could limit its growth and development.
• Debt: OmniAb has no outstanding debt as of now. However, the company may need to incur debt in the future to finance its operations or clinical trials, which could increase its financial risk.

Operational Risk

• Clinical trial setbacks: Clinical trials are complex and unpredictable. OmniAb's clinical trials may experience delays, adverse events, or other setbacks that could impact the development and regulatory approval process for OA101 and other pipeline candidates.
• Manufacturing risk: OmniAb's ability to manufacture OA101 and other pipeline candidates on a commercial scale is critical to its success. The company faces the risk of manufacturing delays, quality control issues, or supply chain disruptions.
• Key personnel risk: OmniAb's success depends on the expertise and experience of its key personnel. The loss of key employees could negatively impact the company's operations and development.

Other Risks

• Reputational risk: Negative publicity or events related to OmniAb or its products could damage the company's reputation and affect its ability to attract patients, investors, and partners.
• Political and regulatory risk: OmniAb's operations are subject to political and regulatory changes in the countries where it operates. Changes in laws or regulations could impact the company's business or operations.
• Cybersecurity risk: OmniAb holds sensitive patient and research data that could be vulnerable to cybersecurity breaches. The company must implement robust cybersecurity measures to protect this data from unauthorized access or misuse.